Expanded Access Program for Alzheimer’s
Hope for those who need it most.
An FDA-approved Expanded Access Program (also known as compassionate use) is available for patients with Alzheimer’s disease who have no remaining treatment options and are not eligible for clinical trials. This program provides access to a promising investigational therapy under carefully monitored conditions.
About the Treatment
A new approach in Alzheimer’s treatment.
This investigational therapy is a humanized monoclonal antibody designed to treat Alzheimer’s disease. It specifically targets galectin-3 (Gal3), a protein linked to the formation of amyloid plaques—a major contributor to Alzheimer’s progression.
Targeting the source of neurodegeneration.
The therapy available through the FDA-approved Expanded Access Program targets galectin-3, a protein involved in amyloid-beta (Aβ) aggregation. By helping reduce this clumping process, it may also limit the formation of tau tangles—two key hallmarks of Alzheimer’s disease.
Blocks Gal3
Reduces Aβ and Tau
Slows or Reverses Decline
Promising results across multiple phases.
The therapy available through the FDA-approved Expanded Access Program has been evaluated in a Phase 1b/2 clinical trial, showing early signs of cognitive benefit and potential disease slowing in patients with mild to severe Alzheimer’s disease.
Potential Benefits of this treatment
Restoring function and preserving memory.
Early results show the therapy may provide potential benefits.
Common questions about our treatment.
Is the therapy safe?
Yes, early safety trials suggest the therapy is generally well-tolerated.
Some patients may experience mild infusion reactions, such as fever, rash, or nausea, which are usually manageable under medical supervision.
Is this therapy being studied for other conditions?
Yes, the therapy is also being researched beyond Alzheimer’s disease.
It is currently in a Phase 2 trial for acute ischemic stroke, and researchers continue to explore its potential across other neurological conditions.